{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022604","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.669672+00:00","generated_at":"2026-06-22T05:32:26.811061+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fulgent Genetics Q3 core revenue up 110% to $56M; acquires Fulgent Pharma for ~$100M","bullets":["Q3 revenue $105.7M (down 54% YoY due to COVID decline); GAAP EPS $0.06, non-GAAP EPS $0.32.","Core revenue (ex-COVID) grew 110% YoY to $56.0M; adjusted EBITDA $19.7M.","Acquired Fulgent Pharma for ~$100M (cash + stock), a clinical-stage therapeutics company with nano-drug delivery platform.","Lead candidate FID-007 for head & neck cancer; combined company offers vertically integrated oncology precision medicine.","Cash, cash equivalents and investments of $918.0M as of Sep 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022604","json":"https://secwatch.observer/filing/0000950170-22-022604.json","markdown":"https://secwatch.observer/filing/0000950170-22-022604.md","text":"https://secwatch.observer/filing/0000950170-22-022604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/0000950170-22-022604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/flgt-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:32:26.811061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5018dac9003eb4fd1ff4b4f5b0c37f3fd79c73a","claim":"Fulgent Genetics, Inc. reported third quarter ended September 30, 2022 results: revenue $105.7 million, net income $1.7 million, EPS $0.06 per share.","evidence_excerpt":"Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2022 Financial Results • Revenue totals $105.7 million • Core Revenue grows 110% year-over-year to $56.0 million TEMPLE CITY, CA, November 7, 2022 —Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/0000950170-22-022604-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$105.7 million"},{"label":"Net income","value":"$1.7 million"},{"label":"EPS","value":"$0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}